DÉRIVÉ DE PYRIDO[3,4-d]PYRIMIDINE ET SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI
- 专利权人:
- Teijin Pharma Limited
- 发明人:
- 申请号：
- EP16803266.2
- 公开号：
- EP3305785A1
- 申请日:
- 2016.05.27
- 申请国别(地区):
- EP
- 年份:
- 2018
- 代理人:
- 摘要：
- The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.
- 来源网站：
- 中国工程科技知识中心
相关发明人
相关专利
- DÉRIVÉ DE PYRIDO[3,4-d]PYRIMIDINE ET SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI
- DERIVE DE PYRIDO[3,4-D]PYRIMIDINE ET SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI
- 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido(2,3-d)pyrimidin-6-yl)phenyl)urea as Raf kinase inhibitor for the treatment of cancer
- COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE
- SEL SERVANT D'INHIBITEUR D'AKT ET CRISTAL DE CELUI-CI
